Related Experiment Video

Updated: May 7, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

siRNA-participated chemotherapy: an efficient and specific therapeutic against gastric cancer

Donglei Zhou1, Xun Jiang, Weixing Ding

  • 1General Surgery Department, The Tenth People's Hospital Affiliated to Tongji University, No. 301 Yanchang Middle Road, Zhabei District, Shanghai 200072, China.

Journal of Cancer Research and Clinical Oncology
|October 1, 2013
PubMed
Abstract

Insights

siRNA effectively suppresses fibroblast growth factor receptor (FGFR) in gastric cancer cells, inhibiting proliferation and promoting apoptosis. This approach enhances chemotherapy effectiveness and may offer a novel therapeutic strategy for gastric cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Gastric cancer remains a significant global health challenge.
  • Fibroblast growth factor receptor (FGFR) signaling pathways are implicated in various cancers, including gastric cancer.
  • Targeting FGFR presents a potential strategy for improving gastric cancer treatment outcomes.

Purpose of the Study:

  • To investigate the efficacy of siRNA-mediated silencing of fibroblast growth factor receptor (FGFR) expression in enhancing chemotherapy for gastric cancer.
  • To elucidate the underlying mechanisms by which FGFR silencing impacts gastric cancer cell behavior and tumor growth.
  • To evaluate the combined therapeutic effect of siRNA and cisplatin in gastric cancer models.

Main Methods:

  • Human gastric cancer cells (MGC80-3) and an in vivo gastric cancer animal model were utilized.
  • Cells and tumors were treated with cisplatin, siRNA targeting FGFR, or a combination thereof.
  • FGFR expression, cell proliferation, apoptosis, and related protein levels (VEGFR, caspase-3, Bax) were assessed using immunofluorescence, MTT assay, flow cytometry, and Western blot.
  • Tumor growth and histopathology were analyzed in the animal model.

Main Results:

  • siRNA treatment significantly reduced FGFR expression, inhibited cell proliferation, and promoted apoptosis in vitro.
  • siRNA also led to decreased VEGFR expression and increased apoptosis-related proteins (caspase-3).
  • In vivo, siRNA suppressed FGFR expression and tumor growth, with combination therapy showing superior antitumor effects.

Conclusions:

  • siRNA effectively suppresses FGFR expression, leading to reduced proliferation and enhanced apoptosis in gastric cancer cells.
  • siRNA demonstrates antitumor effects in vivo by inhibiting tumor growth and FGFR production.
  • siRNA-based chemotherapy represents a promising therapeutic approach for gastric cancer treatment.

More Related Videos

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...